drugset / Trial / NCT04185090

To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults

NCT04185090

Phase 1 Unknown 30 enrolled IlDong Pharmaceutical Co Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is designated to evaluate the pharmacokinetic interactions of valsartan, amlodipine besylate, rosuvastatin, and ezetimibe in healthy male volunteers.

Timeline

Start
2020-02
Primary completion
2020-04
Completion
2020-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 10 mg
Subject Ezetimibe Unknown 10 mg
Subject Rosuvastatin Small molecule 20.8 mg
Subject Valsartan Small molecule 160 mg